In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.

Cannabigerol (CBG) is a minor non-psychoactive cannabinoid present in Cannabis sativa L. (C. sativa) at low levels (<1% per dry weight) that serves as the direct precursor to both cannabidiol (CBD) and tetrahydrocannabinol (THC). Consequently, efforts to extract and purify CBG from C. sativa is both challenging and expensive. However, utilizing a novel yeast fermentation technology platform, minor cannabinoids such as CBG can be produced in a more sustainable, cost-effective, and timely process as compared to plant-based production. While CBD has been studied extensively, demonstrating several beneficial skin properties, there are a paucity of studies characterizing the activity of CBG in human skin. Therefore, our aim was to characterize and compare the in vitro activity profile of non-psychoactive CBG and CBD in skin and be the first group to test CBG clinically on human skin. Gene microarray analysis conducted using 3D human skin equivalents demonstrates that CBG regulates more genes than CBD, including several key skin targets. Human dermal fibroblasts (HDFs) and normal human epidermal keratinocytes (NHEKs) were exposed in culture to pro-inflammatory inducers to trigger cytokine production and oxidative stress. Results demonstrate that CBG and CBD reduce reactive oxygen species levels in HDFs better than vitamin C. Moreover, CBG inhibits pro-inflammatory cytokine (Interleukin-1ß, -6, -8, tumor necrosis factor α) release from several inflammatory inducers, such as ultraviolet A (UVA), ultraviolet B (UVB), chemical, C. acnes, and in several instances does so more potently than CBD. A 20-subject vehicle-controlled clinical study was performed with 0.1% CBG serum and placebo applied topically for 2 weeks after sodium lauryl sulfate (SLS)-induced irritation. CBG serum showed statistically significant improvement above placebo for transepidermal water loss (TEWL) and reduction in the appearance of redness. Altogether, CBG's broad range of in vitro and clinical skin health-promoting activities demonstrates its strong potential as a safe, effective ingredient for topical use and suggests there are areas where it may be more effective than CBD.

A Comparison of the National Football League's Annual National Football League Combine 1999-2000 to 2015-2016.

Fitzgerald, CF and Jensen, RL. A Comparison of the National Football League's annual National Football League combine 1999-2000 to 2015-2016. J Strength Cond Res 34(3): 771-781, 2020-The purpose of this study was to determine if elite football players are becoming bigger, faster, and stronger over the past decade by analyzing individual performances at the National Football League's (NFL) Combine. This study was conducted with (N = 1,263) subjects from the 1999-2000 (99-00) NFL Combines (n = 635) and the 2015-2016 (15-16) NFL Combines (n = 628) separated by position. Data were collected for height, body mass, 40-yd (36.58 m) dash, NFL 225 lb. (102.06 kg) repetitions test, vertical jump (VJ), broad jump (BJ), pro-agility shuttle, and 3-cone drill. Statistical significance between the years for all subjects participating in the NFL Combine was found for the 40-yd dash (99-00: mean ± SD = 4.85 ± 3.2; 15-16: 4.80 ± 3.5; p = 0.002) and VJ (99-00 = 82.04 ± 10.36 and 83.46 ± 10.59; p = 0.028) at the alpha p < 0.05 level. Statistical significance was also found for BJ (99-00 = 111.37 ± 8.81; 15-16: 115.03 ± 9.22; p < 0.001) and the 3-cone drill (99-00 = 7.41 ± 0.42; 15-16: 7.29 ± 4.1; p < 0.001) at the alpha p < 0.001 level. There were no statistically significant findings (p > 0.05) for mass or height found across all subjects by combine years. Results indicate that elite football players have improved their performance, when comparing results from 1999-2000 to 2015-2016. These finding may be beneficial to NFL franchises in their prospective player assessments.